[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio80ee858f":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":77},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio80ee858f","HIMS暴跌后，公司创始人兼CEO回应","\u002Fdoc\u002Fhims暴跌后公司创始人兼ceo回应_1401677981","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">在美国（\u003C\u002Fspan>FDA\u003Cspan style=\"font-family: DengXian;\">）在解决了诺和诺德\u003C\u002Fspan>(NVO)\u003Cspan style=\"font-family: DengXian;\">旗下减肥药\u003C\u002Fspan>Wegovy\u003Cspan style=\"font-family: DengXian;\">和\u003C\u002Fspan>2\u003Cspan style=\"font-family: DengXian;\">型糖尿病药\u003C\u002Fspan>Ozempic\u003Cspan style=\"font-family: DengXian;\">中的活性成分司美格鲁肽已经摆脱短缺状态后，\u003C\u002Fspan>Hims\u003Cspan style=\"font-family: DengXian;\">股价大跌，公司创始人兼\u003C\u002Fspan>CEO\u003Cspan style=\"font-family: DengXian;\">回应：减肥药短缺我会尽可能选择一手消息，来帮助大家更清楚的了解事实原来的样子，以下为原文：\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-size: large;\">HIMS \u003Cspan style=\"font-family: DengXian;\">的核心是一个简单而强大的想法：我们使用精准医学来个性化现有的临床研究药物的交付。我们没有绕过监管程序或创造新药。我们专注于通过个性化提供更好的护理\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">精准医疗是指在正确的时间为正确的患者使用正确的工具，并且通过战略创新变得更好。我们的整体方法意味着越来越多地整合实验室工作、提供商参与、患者选择和临床数据，确保个性化服务是周到、安全、基于证据和以患者为中心的\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">我们相信这种方法最终将带来更好的临床结果。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">我们致力于诚信和透明。在数据证实之前，我们不会声称疗效有所改善。我们展示了我们的质量和安全流程。我们采取一种逻辑方法，让患者和提供者得出自己的结论，因为我们知道，患者，而不是制药利润，应该推动我们的医疗保健系统。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">显然，个性化的关键是需要复合药物。在我们目前的卫生系统中，我们在两种非常特殊的情况下\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-family: DengXian; font-size: large;\">这样做：\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">药物短缺：我们确保患者继续以实惠的价格访问。虽然大型制药公司收取数千美元的费用，但我们通过让人们以数百美元的价格获得药物来填补这一空白\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">临床必要性：当市售的治疗方案不能满足个体患者的需求时，无论是在剂量、给药方式还是对其他成分的需求，我们都能提供个性化治疗\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">我们这样做是因为这对患者来说是正确的。我们不复配每种药物，即使我们相信这会帮助我们的利润。例如，我们从未选择复合\u003C\u002Fspan>tirzepatide\u003Cspan style=\"font-family: DengXian;\">，即使它可能是有利可图的。为什么不呢？在一定程度上，其广泛的市售剂量支持较低的副作用特征，减少了个体需要改变以满足其需求的可能性\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-size: large;\">\u003Cspan style=\"font-family: DengXian;\">我们做复方索马鲁肽。既然\u003C\u002Fspan>FDA \u003Cspan style=\"font-family: DengXian;\">已经确定\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan style=\"font-size: large;\">Semaglutide\u003Cspan style=\"font-family: DengXian;\">的药物短缺问题已经解决\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>","https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202502-stk\u002FUploader0zayyrgnl4v_2025_02_22_10_20_16.png","2025-02-22T18:18:50.543","2025.02.22","2025\u002F02\u002F22",58146,[22],"HIMS","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":68,"summaryHtml":73,"aboutTitle":74,"aboutHtml":75,"copyrightHtml":76},[44,47,50,53,56,59,62,65],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fplan",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":60,"url":61},"美股课程","\u002Fcol\u002Fvideos",{"label":63,"url":64},"免责声明","\u002Fdisclaimer",{"label":66,"url":67},"联系我们","\u002FContactUs",[69,70,71,72],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 StockWe.com 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理千万级股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":78,"search":79,"searchPlaceholder":79,"hotContent":80,"draft":81,"noData":82,"searchNoData":83,"edit":84,"editVideo":85,"courseContent":86,"more":87,"buyNow":88,"subscribeNow":89,"encoding":90,"paidContent":91},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]